Technically Speakin...
Health Care: Drugs
Hemispherx Biopharma Inc. (HEB: AMEX)
$0.27 0.00 | 0.00%
06/04/12 - 01:03 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 0.27 |
| 52 Week High | 0.51 |
| 52 Week Low | 0.17 |
| Avg. Daily Vol. (Mil) | 0.23 |
| Beta (3 year) | 1.19 |
| Share Related Items | |
| Mkt Cap (Mil) | 36.71 |
| Shares Out (Mil) | 135.95 |
| Float (Mil) | 133.42 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 5.40 |
| Current Ratio | 5.60 |
| LT Debt/ Equity | 0.02 |
| Total Debt / Equity | 0.08 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 192.18 |
| Price/Book | 1.02 |
| Price/Cash Flow | -3.70 |
| Per Share Data | |
| Earnings | -0.09 |
| Sales | 0.00 |
| Book Value | 0.27 |
| Cash Flow | -0.07 |
| Business Summary | |
|---|---|
| Hemispherx Biopharma, Inc. is a biopharmaceutical company, engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. | |
| General Information | |
| 1617 JFK Boulevard
Philadelphia, PA 19103 |
|
| www.hemispherx.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 47 | |
| CEO: William A. Carter,M.D. | |
| Short Interest | |
| Current Month (Mil) | 3.21 |
| Previous Month (Mil) | 3.24 |
| Short Interest Ratio (Days) | 20.60 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -24.50 |
| Return on Investments | -28.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with HEB
- Portfolio NameUser Type
- Uservlady 1
- ContributorBarron's Insider Purchases ...
- ContributorBarron's Insider Purchases ...
- Usermaybe will work?
- UserTornado Portfolio
- Userjimb Portfolio 1
- Usergenomics
- User5for5
- Userjoe today
- UserNathan88
Latest HEB Headlines from TheStreet
- Hemisphrex Biopharma Announces Fiscal 2010 Year Results 03.29.11 | 01:03 pm
- Hemispherx Biopharma Reports On Annual Stockholder Meeting 03.22.11 | 02:03 pm
- Hemispherx Biopharma Announces 9th Clinical Investigators Conference: Ampligen Clinical Trials Highlighted 03.07.11 | 02:03 pm
- Chronix Biomedical And Hemispherx Biopharma Jointly File Patent Application For A Blood Test For Chronic Fatigue Syndrome (CFS) 03.03.11 | 10:03 am
- Hemispherx Biopharma Annual Meeting Set 02.24.11 | 08:02 am
- Hemispherx Biopharma, Inc. Announces It Has Scheduled Its 2010 Annual Stockholders' Meeting To Occur On March 17, 2011 In Remediation Of Notice From The NYSE Amex Of Non-Compliance With The Requirement To Hold Its Annual Stockholders' Meeting By The End Of 2010 02.23.11 | 01:02 pm
- Hemispherx Biopharma Appoints Senior Pharma Executive To Key Manufacturing Position 02.17.11 | 10:02 am
- Hemispherx Biopharma Announces US District Court Grants Final Approval Of Settlement Of Securities Class Actions 02.17.11 | 08:02 am
- FDA Authorizes Alferon LDO Clinical Study For Treatment And Prevention Of Influenza 01.04.11 | 10:01 am
- Hemispherx Biopharma, Inc. To Restate 2009 Financial Statements 12.28.10 | 04:12 pm
Press Releases for HEB
- Securities Class Action Filed By Shepherd, Finkelman, Miller & Shah, LLP On Behalf Of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 And November 2, 2009 - PR Newswire 12.08.09 | 04:12 pm
Partner Headlines for HEB
- Oink Oink: Profit From The Return Of Swine Flu - Benzinga 01.12.12 | 01:01 pm
- UPDATE 1-Hemispherx awarded $188 mln in "illegal" takeover suit - Reuters 08.18.10 | 12:08 pm
